Diagnostic biomarkers of ischemic stroke: strengths and limitations across blood, urine, and saliva
Clinical Scorecard: Biomarkers for Diagnosing Ischemic Stroke: Evaluating the Advantages and Disadvantages of Blood, Urine, and Saliva Samples
At a Glance
| Category | Detail |
|---|
| Condition | Ischemic Stroke |
| Key Mechanisms | Neuronal injury, inflammation, hemostasis, oxidative stress |
| Target Population | Patients suspected of having ischemic stroke |
| Care Setting | Prehospital and low-resource settings |
Key Highlights
- Ischemic stroke is a leading cause of death and disability worldwide.
- Neuroimaging is the preferred diagnostic method but may not be available in all settings.
- Blood-based biomarkers are the most advanced for early stroke subtyping.
- No single biomarker is currently sufficient for early ischemic stroke diagnosis.
- Future strategies may rely on multi-marker approaches and standardized methods.
Guideline-Based Recommendations
Diagnosis
- Clinical assessment combined with neuroimaging methods such as CT and MRI.
Management
- Timely reperfusion is critical within the first 4.5 hours of ischemic stroke onset.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with suspected ischemic stroke
Intravenous thrombolytics (t-PA) are administered within a narrow time window.
Clinical Best Practices
- Utilize neuroimaging for accurate diagnosis when available.
- Consider biomarkers as adjuncts to clinical assessment in low-resource settings.
Related Resources & Content
